Purple Biotech (PPBT) Short-term Investments (2016 - 2026)
Purple Biotech (PPBT) posted quarterly Short-term Investments of $859000.0 for Q1 2026, up 1.54% year-over-year from $846000.0 in Q1 2025, and little changed quarter-over-quarter from $857000.0 in Q4 2025.
Purple Biotech (PPBT) Short-term Investments (2016 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Short-term Investments for 11 consecutive years, with $859000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments rose 1.54% year-over-year to $859000.0; the TTM figure through Mar 2026 stood at $859000.0 (up 1.54% YoY), while the FY2025 annual figure was $857000.0, up 211.64% from the prior year.
- Short-term Investments steadied at $859000.0 in Q1 2026 per PPBT's latest filing, from $857000.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $22.0 million in Q2 2022 and bottomed at $275000.0 in Q4 2024.
- Historically, Short-term Investments has averaged $4.2 million across 5 years, with a median of $849000.0 in 2023.
- Annual changes were most pronounced in 2022 — Short-term Investments plunged 98.81% — and 2025, when it surged 211.64%.
- Purple Biotech's Short-term Investments stood at $431000.0 in 2022, then jumped by 97.22% to $850000.0 in 2023, then slumped by 67.65% to $275000.0 in 2024, then soared by 211.64% to $857000.0 in 2025, then grew by 0.23% to $859000.0 in 2026.
- Business Quant data shows PPBT's Short-term Investments at $859000.0 in Q1 2026, $857000.0 in Q4 2025, and $862000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 859,000.00 |
| Dec 31, 2025 | 857,000.00 |
| Sep 30, 2025 | 862,000.00 |
| Jun 30, 2025 | 857,000.00 |
| Mar 31, 2025 | 846,000.00 |
| Dec 31, 2024 | 275,000.00 |
| Sep 30, 2024 | 848,000.00 |
| Jun 30, 2024 | 845,000.00 |
| Mar 31, 2024 | 848,000.00 |
| Dec 31, 2023 | 850,000.00 |
| Sep 30, 2023 | 842,000.00 |
| Jun 30, 2023 | 846,000.00 |
| Mar 31, 2023 | 849,000.00 |
| Dec 31, 2022 | 431,000.00 |
| Sep 30, 2022 | 22.01 Mn |
| Jun 30, 2022 | 22.01 Mn |
| Mar 31, 2022 | 16.01 Mn |
| Dec 31, 2021 | 36.31 Mn |
| Sep 30, 2021 | 36.45 Mn |
| Jun 30, 2021 | 37.85 Mn |